The Myeloma Trial Finder lists the clinical trials that are currently recruiting in the UK. If you are thinking about joining a clinical trial you should talk to your healthcare team to find out if this is a suitable option for you.
Further information can be found on our website under Clinical Trials and Novel Drugs or if you would like to speak to someone please call the Myeloma UK infoline on 0800 980 3332
Recruitment to clinical trials may be paused at some hospitals due to the COVID-19 pandemic. Your healthcare team can provide additional details about recruitment to clinical trials in your area.
Last update: 13/05/2022
There are currently 26 open trials.
In 111 locations
What is a Clinical Trial?
There are currently 26 open trials
- Cilta-cel CAR-T cell therapy for newly diagnosed myeloma patients
- Elranatamab for relapsed and/or refractory myeloma (MagnetisMM-9)
- Teclistamab in combination with daratumumab for relapsed and/or refractory myeloma (MajesTEC-3)
- ANV419 for advanced cancer or relapsed myeloma
- Escalating doses of RO7425781 for relapsed and/or refractory myeloma
- CID-103 for Relapsed and/or Refractory Myeloma
- Belantamab mafodotin plus pomalidomide and dexamethasone for treatment of relapsed and/or refractory myeloma (DREAMM-8)
- Isatuximab in combination with lenalidomide and dexamethasone for high-risk smouldering myeloma (ITHACA)
- Teclistamab combination treatments for myeloma
- Improving the early detection of myeloma in smouldering myeloma patients (COSMOS)
- CAEL-101 in AL amyloidosis patients (Mayo stage IIIa)
- CAEL-101 in AL amyloidosis patients (Mayo stage IIIb)
- Belantamab mafodotin with bortezomib, lenalidomide and dexamethasone for newly diagnosed myeloma (DREAMM 9)
- Adaptive treatment in newly diagnosed myeloma patients not eligible for HDT-SCT (FiTNEss, Myeloma XIV)
- Evaluating patient-based treatment strategies for newly diagnosed myeloma patients (RADAR)
- Belantamab mafodotin versus pomalidomide and dexamethasone for treatment of relapsed and/or refractory myeloma (DREAMM-3)
- A clinical trial evaluating VS-6766 for the treatment of refractory myeloma patients
- CCS1477 for the treatment of relapsed/refractory myeloma patients
- Oxford pre-cancerous disorders study (OxPLoreD)
- A study evaluating S65487 for the treatment of relapsed/refractory myeloma patients
- bb2121 CART-Cells in relapsed/refractory and high-risk myeloma (KarMMa-2)
- Venetoclax and dexamethasone in patients with relapsed or refractory myeloma (CANOVA)
- Trial of immunomodulatory therapy in high risk solitary bone plasmacytoma (IDRIS)
- CC-92480 for relapsed and refractory multiple myeloma
- CC-220 (iberdomide) as a monotherapy and in combination with other treatments
- Myeloma XII (ACCoRd)
Trial Title:
Cilta-cel CAR-T cell therapy for newly diagnosed myeloma patients
Treatments:
Cilta-cel (Ciltacabtagene autoleucel)
Bortezomib (Velcade®)
Lenalidomide (Revlimid®)
Dexamethasone
Myeloma stage:
Newly Diagnosed
Trial phase:
III
Summary:
This trial is investigating how cilta-cel, a type of treatment known as chimeric antigen receptor T cell (CAR T Cell) therapy, compares to the combination of lenalidomide (Revlimid®) and dexamethasone for the treatment of newly diagnosed myeloma patients.
Locations:
University College Hospital, London;
King's College Hospital, London
Who can enter the study?:
Newly diagnosed myeloma patients who are not eligible for high-dose therapy and stem cell transplantation (HDT-SCT).
What's involved?:
All patients will receive bortezomib (Velcade®), lenalidomide, and dexamethasone (VRd) regimen for six cycles before randomization. Patients will then be randomly allocated into Group A or Group B.
Patients in Group A will receive two more cycles of VRd. Group A will then receive lenalidomide and dexamethasone (Rd) maintenance therapy until there are signs of disease progression or it is discontinued for other reasons.
Patients in Group B will undergo leukapheresis (T cell harvest) after six cycles of VRd. The harvested T cells are then modified to become the CAR-T cell treatment. Patients will then receive two more cycles of VRd. Patients will then receive the cilta-cel treatment by intravenous infusion (into a vein).
Patients will be required to regularly fill in surveys, and attend outpatient clinics for regular check-ups and blood tests.
Patients will be followed up for up to 12 years and 5 months.
Clinical Information
(for Medical Professionals):
A randomised, open-label, phase III clinical trial evaluating the safety and efficacy of cilta-cel compared to lenalidomide and dexamethasone (Rd) maintenance therapy for the treatment of newly diagnosed myeloma patients, who are not eligible for HDT-SCT.
Find out more about Myeloma UK:
Visit www.myeloma.org.uk